Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Enanta Pharmaceuticals Inc | ENTA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
16.53 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 8.08 - 41.45 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 16.53 | USD |
Enanta Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
349.71M | 21.16M | - | 79.2M | -133.82M | -6.33 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Enanta Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ENTA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 14.50 | 17.01 | 13.86 | 15.39 | 374,844 | 2.03 | 14.00% |
1 Month | 14.35 | 17.01 | 13.47 | 15.07 | 252,523 | 2.18 | 15.19% |
3 Months | 10.60 | 17.01 | 10.60 | 13.19 | 275,200 | 5.93 | 55.94% |
6 Months | 11.42 | 17.01 | 8.08 | 11.16 | 277,671 | 5.11 | 44.75% |
1 Year | 39.65 | 41.45 | 8.08 | 15.65 | 294,382 | -23.12 | -58.31% |
3 Years | 49.52 | 102.00 | 8.08 | 38.83 | 226,153 | -32.99 | -66.62% |
5 Years | 94.47 | 104.03 | 8.08 | 45.97 | 206,375 | -77.94 | -82.50% |
Enanta Pharmaceuticals Description
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline. |